269 related articles for article (PubMed ID: 31270216)
1. Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators.
Bruen R; Curley S; Kajani S; Lynch G; O'Reilly ME; Dillon ET; Brennan EP; Barry M; Sheehan S; McGillicuddy FC; Belton O
J Pharmacol Exp Ther; 2019 Sep; 370(3):447-458. PubMed ID: 31270216
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis.
Bruen R; Curley S; Kajani S; Crean D; O'Reilly ME; Lucitt MB; Godson CG; McGillicuddy FC; Belton O
Cardiovasc Diabetol; 2017 Nov; 16(1):143. PubMed ID: 29110715
[TBL] [Abstract][Full Text] [Related]
3. Different monocyte phenotypes result in proresolving macrophages in conjugated linoleic acid-induced attenuated progression and regression of atherosclerosis.
Bruen R; Curley S; Kajani S; Lynch G; O'Reilly ME; Dillon ET; Fitzsimons S; Mthunzi L; McGillicuddy FC; Belton O
FASEB J; 2019 Oct; 33(10):11006-11020. PubMed ID: 31284764
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice.
Li P; Tang Z; Wang L; Feng B
Mol Med Rep; 2017 Sep; 16(3):3421-3426. PubMed ID: 28713911
[TBL] [Abstract][Full Text] [Related]
5. IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis.
Erbel C; Akhavanpoor M; Okuyucu D; Wangler S; Dietz A; Zhao L; Stellos K; Little KM; Lasitschka F; Doesch A; Hakimi M; Dengler TJ; Giese T; Blessing E; Katus HA; Gleissner CA
J Immunol; 2014 Nov; 193(9):4344-55. PubMed ID: 25261478
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.
Jojima T; Uchida K; Akimoto K; Tomotsune T; Yanagi K; Iijima T; Suzuki K; Kasai K; Aso Y
Atherosclerosis; 2017 Jun; 261():44-51. PubMed ID: 28445811
[TBL] [Abstract][Full Text] [Related]
7. Insulin-Like Growth Factor-1 Receptor Deficiency in Macrophages Accelerates Atherosclerosis and Induces an Unstable Plaque Phenotype in Apolipoprotein E-Deficient Mice.
Higashi Y; Sukhanov S; Shai SY; Danchuk S; Tang R; Snarski P; Li Z; Lobelle-Rich P; Wang M; Wang D; Yu H; Korthuis R; Delafontaine P
Circulation; 2016 Jun; 133(23):2263-78. PubMed ID: 27154724
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E-/- Mice Lacking Hemopexin Develop Increased Atherosclerosis via Mechanisms That Include Oxidative Stress and Altered Macrophage Function.
Mehta NU; Grijalva V; Hama S; Wagner A; Navab M; Fogelman AM; Reddy ST
Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1152-63. PubMed ID: 27079878
[TBL] [Abstract][Full Text] [Related]
9. Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms.
Koshibu M; Mori Y; Saito T; Kushima H; Hiromura M; Terasaki M; Takada M; Fukui T; Hirano T
Am J Physiol Endocrinol Metab; 2019 May; 316(5):E895-E907. PubMed ID: 30860874
[TBL] [Abstract][Full Text] [Related]
10. Skin-Derived Mesenchymal Stem Cells Alleviate Atherosclerosis via Modulating Macrophage Function.
Li Q; Sun W; Wang X; Zhang K; Xi W; Gao P
Stem Cells Transl Med; 2015 Nov; 4(11):1294-301. PubMed ID: 26400926
[TBL] [Abstract][Full Text] [Related]
11. Murine Norovirus Infection Variably Alters Atherosclerosis in Mice Lacking Apolipoprotein E.
Hsu CC; Paik J; Brabb TL; O'Brien KD; Kim J; Sullivan BG; Hudkins KL; Seamons A; Finley JC; Meeker SM; Maggio-Price L
Comp Med; 2015 Oct; 65(5):369-81. PubMed ID: 26473341
[TBL] [Abstract][Full Text] [Related]
12. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model.
Gaspari T; Welungoda I; Widdop RE; Simpson RW; Dear AE
Diab Vasc Dis Res; 2013 Jul; 10(4):353-60. PubMed ID: 23673376
[TBL] [Abstract][Full Text] [Related]
13. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.
Tashiro Y; Sato K; Watanabe T; Nohtomi K; Terasaki M; Nagashima M; Hirano T
Peptides; 2014 Apr; 54():19-26. PubMed ID: 24418070
[TBL] [Abstract][Full Text] [Related]
14. Role of endothelial cell-derived angptl2 in vascular inflammation leading to endothelial dysfunction and atherosclerosis progression.
Horio E; Kadomatsu T; Miyata K; Arai Y; Hosokawa K; Doi Y; Ninomiya T; Horiguchi H; Endo M; Tabata M; Tazume H; Tian Z; Takahashi O; Terada K; Takeya M; Hao H; Hirose N; Minami T; Suda T; Kiyohara Y; Ogawa H; Kaikita K; Oike Y
Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):790-800. PubMed ID: 24526691
[TBL] [Abstract][Full Text] [Related]
15. Smooth Muscle Cell-Derived Interleukin-17C Plays an Atherogenic Role via the Recruitment of Proinflammatory Interleukin-17A+ T Cells to the Aorta.
Butcher MJ; Waseem TC; Galkina EV
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1496-506. PubMed ID: 27365405
[TBL] [Abstract][Full Text] [Related]
16. Nrf2 in bone marrow-derived cells positively contributes to the advanced stage of atherosclerotic plaque formation.
Harada N; Ito K; Hosoya T; Mimura J; Maruyama A; Noguchi N; Yagami K; Morito N; Takahashi S; Maher JM; Yamamoto M; Itoh K
Free Radic Biol Med; 2012 Dec; 53(12):2256-62. PubMed ID: 23051009
[TBL] [Abstract][Full Text] [Related]
17. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.
Tang ZH; Peng J; Ren Z; Yang J; Li TT; Li TH; Wang Z; Wei DH; Liu LS; Zheng XL; Jiang ZS
Atherosclerosis; 2017 Jul; 262():113-122. PubMed ID: 28535426
[TBL] [Abstract][Full Text] [Related]
18. Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice.
Hara T; Phuong PT; Fukuda D; Yamaguchi K; Murata C; Nishimoto S; Yagi S; Kusunose K; Yamada H; Soeki T; Wakatsuki T; Imoto I; Shimabukuro M; Sata M
Circulation; 2018 Oct; 138(16):1706-1719. PubMed ID: 29700120
[TBL] [Abstract][Full Text] [Related]
19. Ultrasound Biomicroscopic Imaging for Interleukin-1 Receptor Antagonist-Inhibiting Atherosclerosis and Markers of Inflammation in Atherosclerotic Development in Apolipoprotein-E Knockout Mice.
Li RJ; Sun Y; Wang Q; Yang J; Yang Y; Song L; Wang Z; Luo XH; Su RJ
Tex Heart Inst J; 2015 Aug; 42(4):319-26. PubMed ID: 26413013
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-1 receptor type-1 in non-hematopoietic cells is the target for the pro-atherogenic effects of interleukin-1 in apoE-deficient mice.
Shemesh S; Kamari Y; Shaish A; Olteanu S; Kandel-Kfir M; Almog T; Grosskopf I; Apte RN; Harats D
Atherosclerosis; 2012 Jun; 222(2):329-36. PubMed ID: 22236482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
